カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

流行性角結膜炎用治療のグローバル市場2023：局所式、経口式

■ 英語タイトル：Global Epidemic Keratoconjunctivitis Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23AG11425）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23AG11425
■ 発行日：2023年8月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：115
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[流行性角結膜炎用治療のグローバル市場2023：局所式、経口式]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Global Info Research社の最新の調査によると、流行性角結膜炎用治療のグローバル市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
本調査レポートは、世界の流行性角結膜炎用治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本資料の主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 流行性角結膜炎用治療の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

流行性角結膜炎用治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・局所式、経口式

用途別セグメント
・病院薬局、小売薬局、オンライン薬局

主要な市場プレーヤー
・Sanofi S.A、AbbVie Inc.、Santen Pharmaceuticals Co. Ltd、Japan Tobacco Inc.、LeoPharma、Incyte Corporation、Rосhе、Luіtроld、Ваuѕсh & Lоmb、НUВЕІ КЕYІ、Wuhаn Нuаlоng Віо-рhаrmасеutісаl、Basilea Pharmaceuticals and Stiefel Laboratories、Renegeron、Asana Biosciences、Agio Pharmaceuticals Limited、Synmedic Laboratories、Bhavishya Pharmaceuticals Pvt Ltd、Geo Pharma Pvt Ltd

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、流行性角結膜炎用治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な流行性角結膜炎用治療メーカーの企業概要、2019年～2022年までの流行性角結膜炎用治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な流行性角結膜炎用治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別流行性角結膜炎用治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの流行性角結膜炎用治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での流行性角結膜炎用治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および流行性角結膜炎用治療の産業チェーンを掲載しています。
・第14、15章では、流行性角結膜炎用治療の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 流行性角結膜炎用治療の概要
– 種類別分析（2018年vs2022年vs2029年）：局所式、経口式
– 用途別分析（2018年vs2022年vs2029年）：病院薬局、小売薬局、オンライン薬局
– 世界の流行性角結膜炎用治療市場規模・予測
– 世界の流行性角結膜炎用治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Sanofi S.A、AbbVie Inc.、Santen Pharmaceuticals Co. Ltd、Japan Tobacco Inc.、LeoPharma、Incyte Corporation、Rосhе、Luіtроld、Ваuѕсh & Lоmb、НUВЕІ КЕYІ、Wuhаn Нuаlоng Віо-рhаrmасеutісаl、Basilea Pharmaceuticals and Stiefel Laboratories、Renegeron、Asana Biosciences、Agio Pharmaceuticals Limited、Synmedic Laboratories、Bhavishya Pharmaceuticals Pvt Ltd、Geo Pharma Pvt Ltd
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：局所式、経口式
・用途別分析2018年-2029年：病院薬局、小売薬局、オンライン薬局
・流行性角結膜炎用治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・流行性角結膜炎用治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・流行性角結膜炎用治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・流行性角結膜炎用治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・流行性角結膜炎用治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Epidemic Keratoconjunctivitis Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Topical
1.3.3 Oral
1.4 Market Analysis by Application
1.4.1 Overview: Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacy
1.4.3 Retail Pharmacy
1.4.4 Online Pharmacy
1.5 Global Epidemic Keratoconjunctivitis Treatment Market Size & Forecast
1.5.1 Global Epidemic Keratoconjunctivitis Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Epidemic Keratoconjunctivitis Treatment Sales Quantity (2018-2029)
1.5.3 Global Epidemic Keratoconjunctivitis Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sanofi S.A
2.1.1 Sanofi S.A Details
2.1.2 Sanofi S.A Major Business
2.1.3 Sanofi S.A Epidemic Keratoconjunctivitis Treatment Product and Services
2.1.4 Sanofi S.A Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi S.A Recent Developments/Updates
2.2 AbbVie Inc.
2.2.1 AbbVie Inc. Details
2.2.2 AbbVie Inc. Major Business
2.2.3 AbbVie Inc. Epidemic Keratoconjunctivitis Treatment Product and Services
2.2.4 AbbVie Inc. Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 AbbVie Inc. Recent Developments/Updates
2.3 Santen Pharmaceuticals Co. Ltd
2.3.1 Santen Pharmaceuticals Co. Ltd Details
2.3.2 Santen Pharmaceuticals Co. Ltd Major Business
2.3.3 Santen Pharmaceuticals Co. Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
2.3.4 Santen Pharmaceuticals Co. Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Santen Pharmaceuticals Co. Ltd Recent Developments/Updates
2.4 Japan Tobacco Inc.
2.4.1 Japan Tobacco Inc. Details
2.4.2 Japan Tobacco Inc. Major Business
2.4.3 Japan Tobacco Inc. Epidemic Keratoconjunctivitis Treatment Product and Services
2.4.4 Japan Tobacco Inc. Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Japan Tobacco Inc. Recent Developments/Updates
2.5 LeoPharma
2.5.1 LeoPharma Details
2.5.2 LeoPharma Major Business
2.5.3 LeoPharma Epidemic Keratoconjunctivitis Treatment Product and Services
2.5.4 LeoPharma Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 LeoPharma Recent Developments/Updates
2.6 Incyte Corporation
2.6.1 Incyte Corporation Details
2.6.2 Incyte Corporation Major Business
2.6.3 Incyte Corporation Epidemic Keratoconjunctivitis Treatment Product and Services
2.6.4 Incyte Corporation Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Incyte Corporation Recent Developments/Updates
2.7 Rосhе
2.7.1 Rосhе Details
2.7.2 Rосhе Major Business
2.7.3 Rосhе Epidemic Keratoconjunctivitis Treatment Product and Services
2.7.4 Rосhе Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Rосhе Recent Developments/Updates
2.8 Luіtроld
2.8.1 Luіtроld Details
2.8.2 Luіtроld Major Business
2.8.3 Luіtроld Epidemic Keratoconjunctivitis Treatment Product and Services
2.8.4 Luіtроld Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Luіtроld Recent Developments/Updates
2.9 Ваuѕсh & Lоmb
2.9.1 Ваuѕсh & Lоmb Details
2.9.2 Ваuѕсh & Lоmb Major Business
2.9.3 Ваuѕсh & Lоmb Epidemic Keratoconjunctivitis Treatment Product and Services
2.9.4 Ваuѕсh & Lоmb Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Ваuѕсh & Lоmb Recent Developments/Updates
2.10 НUВЕІ КЕYІ
2.10.1 НUВЕІ КЕYІ Details
2.10.2 НUВЕІ КЕYІ Major Business
2.10.3 НUВЕІ КЕYІ Epidemic Keratoconjunctivitis Treatment Product and Services
2.10.4 НUВЕІ КЕYІ Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 НUВЕІ КЕYІ Recent Developments/Updates
2.11 Wuhаn Нuаlоng Віо-рhаrmасеutісаl
2.11.1 Wuhаn Нuаlоng Віо-рhаrmасеutісаl Details
2.11.2 Wuhаn Нuаlоng Віо-рhаrmасеutісаl Major Business
2.11.3 Wuhаn Нuаlоng Віо-рhаrmасеutісаl Epidemic Keratoconjunctivitis Treatment Product and Services
2.11.4 Wuhаn Нuаlоng Віо-рhаrmасеutісаl Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Wuhаn Нuаlоng Віо-рhаrmасеutісаl Recent Developments/Updates
2.12 Basilea Pharmaceuticals and Stiefel Laboratories
2.12.1 Basilea Pharmaceuticals and Stiefel Laboratories Details
2.12.2 Basilea Pharmaceuticals and Stiefel Laboratories Major Business
2.12.3 Basilea Pharmaceuticals and Stiefel Laboratories Epidemic Keratoconjunctivitis Treatment Product and Services
2.12.4 Basilea Pharmaceuticals and Stiefel Laboratories Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Basilea Pharmaceuticals and Stiefel Laboratories Recent Developments/Updates
2.13 Renegeron
2.13.1 Renegeron Details
2.13.2 Renegeron Major Business
2.13.3 Renegeron Epidemic Keratoconjunctivitis Treatment Product and Services
2.13.4 Renegeron Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Renegeron Recent Developments/Updates
2.14 Asana Biosciences
2.14.1 Asana Biosciences Details
2.14.2 Asana Biosciences Major Business
2.14.3 Asana Biosciences Epidemic Keratoconjunctivitis Treatment Product and Services
2.14.4 Asana Biosciences Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Asana Biosciences Recent Developments/Updates
2.15 Agio Pharmaceuticals Limited
2.15.1 Agio Pharmaceuticals Limited Details
2.15.2 Agio Pharmaceuticals Limited Major Business
2.15.3 Agio Pharmaceuticals Limited Epidemic Keratoconjunctivitis Treatment Product and Services
2.15.4 Agio Pharmaceuticals Limited Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Agio Pharmaceuticals Limited Recent Developments/Updates
2.16 Synmedic Laboratories
2.16.1 Synmedic Laboratories Details
2.16.2 Synmedic Laboratories Major Business
2.16.3 Synmedic Laboratories Epidemic Keratoconjunctivitis Treatment Product and Services
2.16.4 Synmedic Laboratories Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Synmedic Laboratories Recent Developments/Updates
2.17 Bhavishya Pharmaceuticals Pvt Ltd
2.17.1 Bhavishya Pharmaceuticals Pvt Ltd Details
2.17.2 Bhavishya Pharmaceuticals Pvt Ltd Major Business
2.17.3 Bhavishya Pharmaceuticals Pvt Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
2.17.4 Bhavishya Pharmaceuticals Pvt Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Bhavishya Pharmaceuticals Pvt Ltd Recent Developments/Updates
2.18 Geo Pharma Pvt Ltd
2.18.1 Geo Pharma Pvt Ltd Details
2.18.2 Geo Pharma Pvt Ltd Major Business
2.18.3 Geo Pharma Pvt Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
2.18.4 Geo Pharma Pvt Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Geo Pharma Pvt Ltd Recent Developments/Updates
3 Competitive Environment: Epidemic Keratoconjunctivitis Treatment by Manufacturer
3.1 Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Epidemic Keratoconjunctivitis Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Epidemic Keratoconjunctivitis Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Epidemic Keratoconjunctivitis Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Epidemic Keratoconjunctivitis Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Epidemic Keratoconjunctivitis Treatment Manufacturer Market Share in 2022
3.5 Epidemic Keratoconjunctivitis Treatment Market: Overall Company Footprint Analysis
3.5.1 Epidemic Keratoconjunctivitis Treatment Market: Region Footprint
3.5.2 Epidemic Keratoconjunctivitis Treatment Market: Company Product Type Footprint
3.5.3 Epidemic Keratoconjunctivitis Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Epidemic Keratoconjunctivitis Treatment Market Size by Region
4.1.1 Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Epidemic Keratoconjunctivitis Treatment Average Price by Region (2018-2029)
4.2 North America Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029)
4.3 Europe Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029)
4.5 South America Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
5.2 Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type (2018-2029)
5.3 Global Epidemic Keratoconjunctivitis Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
6.2 Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application (2018-2029)
6.3 Global Epidemic Keratoconjunctivitis Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
7.2 North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
7.3 North America Epidemic Keratoconjunctivitis Treatment Market Size by Country
7.3.1 North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Epidemic Keratoconjunctivitis Treatment Market Size by Country
8.3.1 Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Market Size by Region
9.3.1 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
10.2 South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
10.3 South America Epidemic Keratoconjunctivitis Treatment Market Size by Country
10.3.1 South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Epidemic Keratoconjunctivitis Treatment Market Size by Country
11.3.1 Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Epidemic Keratoconjunctivitis Treatment Market Drivers
12.2 Epidemic Keratoconjunctivitis Treatment Market Restraints
12.3 Epidemic Keratoconjunctivitis Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Epidemic Keratoconjunctivitis Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Epidemic Keratoconjunctivitis Treatment
13.3 Epidemic Keratoconjunctivitis Treatment Production Process
13.4 Epidemic Keratoconjunctivitis Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Epidemic Keratoconjunctivitis Treatment Typical Distributors
14.3 Epidemic Keratoconjunctivitis Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi S.A Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi S.A Major Business
Table 5. Sanofi S.A Epidemic Keratoconjunctivitis Treatment Product and Services
Table 6. Sanofi S.A Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi S.A Recent Developments/Updates
Table 8. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 9. AbbVie Inc. Major Business
Table 10. AbbVie Inc. Epidemic Keratoconjunctivitis Treatment Product and Services
Table 11. AbbVie Inc. Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. AbbVie Inc. Recent Developments/Updates
Table 13. Santen Pharmaceuticals Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 14. Santen Pharmaceuticals Co. Ltd Major Business
Table 15. Santen Pharmaceuticals Co. Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
Table 16. Santen Pharmaceuticals Co. Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Santen Pharmaceuticals Co. Ltd Recent Developments/Updates
Table 18. Japan Tobacco Inc. Basic Information, Manufacturing Base and Competitors
Table 19. Japan Tobacco Inc. Major Business
Table 20. Japan Tobacco Inc. Epidemic Keratoconjunctivitis Treatment Product and Services
Table 21. Japan Tobacco Inc. Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Japan Tobacco Inc. Recent Developments/Updates
Table 23. LeoPharma Basic Information, Manufacturing Base and Competitors
Table 24. LeoPharma Major Business
Table 25. LeoPharma Epidemic Keratoconjunctivitis Treatment Product and Services
Table 26. LeoPharma Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. LeoPharma Recent Developments/Updates
Table 28. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 29. Incyte Corporation Major Business
Table 30. Incyte Corporation Epidemic Keratoconjunctivitis Treatment Product and Services
Table 31. Incyte Corporation Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Incyte Corporation Recent Developments/Updates
Table 33. Rосhе Basic Information, Manufacturing Base and Competitors
Table 34. Rосhе Major Business
Table 35. Rосhе Epidemic Keratoconjunctivitis Treatment Product and Services
Table 36. Rосhе Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Rосhе Recent Developments/Updates
Table 38. Luіtроld Basic Information, Manufacturing Base and Competitors
Table 39. Luіtроld Major Business
Table 40. Luіtроld Epidemic Keratoconjunctivitis Treatment Product and Services
Table 41. Luіtроld Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Luіtроld Recent Developments/Updates
Table 43. Ваuѕсh & Lоmb Basic Information, Manufacturing Base and Competitors
Table 44. Ваuѕсh & Lоmb Major Business
Table 45. Ваuѕсh & Lоmb Epidemic Keratoconjunctivitis Treatment Product and Services
Table 46. Ваuѕсh & Lоmb Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Ваuѕсh & Lоmb Recent Developments/Updates
Table 48. НUВЕІ КЕYІ Basic Information, Manufacturing Base and Competitors
Table 49. НUВЕІ КЕYІ Major Business
Table 50. НUВЕІ КЕYІ Epidemic Keratoconjunctivitis Treatment Product and Services
Table 51. НUВЕІ КЕYІ Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. НUВЕІ КЕYІ Recent Developments/Updates
Table 53. Wuhаn Нuаlоng Віо-рhаrmасеutісаl Basic Information, Manufacturing Base and Competitors
Table 54. Wuhаn Нuаlоng Віо-рhаrmасеutісаl Major Business
Table 55. Wuhаn Нuаlоng Віо-рhаrmасеutісаl Epidemic Keratoconjunctivitis Treatment Product and Services
Table 56. Wuhаn Нuаlоng Віо-рhаrmасеutісаl Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Wuhаn Нuаlоng Віо-рhаrmасеutісаl Recent Developments/Updates
Table 58. Basilea Pharmaceuticals and Stiefel Laboratories Basic Information, Manufacturing Base and Competitors
Table 59. Basilea Pharmaceuticals and Stiefel Laboratories Major Business
Table 60. Basilea Pharmaceuticals and Stiefel Laboratories Epidemic Keratoconjunctivitis Treatment Product and Services
Table 61. Basilea Pharmaceuticals and Stiefel Laboratories Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Basilea Pharmaceuticals and Stiefel Laboratories Recent Developments/Updates
Table 63. Renegeron Basic Information, Manufacturing Base and Competitors
Table 64. Renegeron Major Business
Table 65. Renegeron Epidemic Keratoconjunctivitis Treatment Product and Services
Table 66. Renegeron Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Renegeron Recent Developments/Updates
Table 68. Asana Biosciences Basic Information, Manufacturing Base and Competitors
Table 69. Asana Biosciences Major Business
Table 70. Asana Biosciences Epidemic Keratoconjunctivitis Treatment Product and Services
Table 71. Asana Biosciences Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Asana Biosciences Recent Developments/Updates
Table 73. Agio Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors
Table 74. Agio Pharmaceuticals Limited Major Business
Table 75. Agio Pharmaceuticals Limited Epidemic Keratoconjunctivitis Treatment Product and Services
Table 76. Agio Pharmaceuticals Limited Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Agio Pharmaceuticals Limited Recent Developments/Updates
Table 78. Synmedic Laboratories Basic Information, Manufacturing Base and Competitors
Table 79. Synmedic Laboratories Major Business
Table 80. Synmedic Laboratories Epidemic Keratoconjunctivitis Treatment Product and Services
Table 81. Synmedic Laboratories Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Synmedic Laboratories Recent Developments/Updates
Table 83. Bhavishya Pharmaceuticals Pvt Ltd Basic Information, Manufacturing Base and Competitors
Table 84. Bhavishya Pharmaceuticals Pvt Ltd Major Business
Table 85. Bhavishya Pharmaceuticals Pvt Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
Table 86. Bhavishya Pharmaceuticals Pvt Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Bhavishya Pharmaceuticals Pvt Ltd Recent Developments/Updates
Table 88. Geo Pharma Pvt Ltd Basic Information, Manufacturing Base and Competitors
Table 89. Geo Pharma Pvt Ltd Major Business
Table 90. Geo Pharma Pvt Ltd Epidemic Keratoconjunctivitis Treatment Product and Services
Table 91. Geo Pharma Pvt Ltd Epidemic Keratoconjunctivitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Geo Pharma Pvt Ltd Recent Developments/Updates
Table 93. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 94. Global Epidemic Keratoconjunctivitis Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 95. Global Epidemic Keratoconjunctivitis Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 96. Market Position of Manufacturers in Epidemic Keratoconjunctivitis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 97. Head Office and Epidemic Keratoconjunctivitis Treatment Production Site of Key Manufacturer
Table 98. Epidemic Keratoconjunctivitis Treatment Market: Company Product Type Footprint
Table 99. Epidemic Keratoconjunctivitis Treatment Market: Company Product Application Footprint
Table 100. Epidemic Keratoconjunctivitis Treatment New Market Entrants and Barriers to Market Entry
Table 101. Epidemic Keratoconjunctivitis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 102. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 103. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 104. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 105. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 106. Global Epidemic Keratoconjunctivitis Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 107. Global Epidemic Keratoconjunctivitis Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 108. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 111. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 112. Global Epidemic Keratoconjunctivitis Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 113. Global Epidemic Keratoconjunctivitis Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 114. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 117. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 118. Global Epidemic Keratoconjunctivitis Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 119. Global Epidemic Keratoconjunctivitis Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 120. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 121. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 122. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 123. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 124. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 125. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 126. North America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 127. North America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 128. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 129. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 130. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 131. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 132. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 133. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 134. Europe Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 135. Europe Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 136. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 137. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 138. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 139. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 140. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 141. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 142. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 143. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 144. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 145. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 146. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 147. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 148. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 149. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 150. South America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 151. South America Epidemic Keratoconjunctivitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 152. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 153. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 154. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 155. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 156. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 157. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 158. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 159. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 160. Epidemic Keratoconjunctivitis Treatment Raw Material
Table 161. Key Manufacturers of Epidemic Keratoconjunctivitis Treatment Raw Materials
Table 162. Epidemic Keratoconjunctivitis Treatment Typical Distributors
Table 163. Epidemic Keratoconjunctivitis Treatment Typical Customers
List of Figures
Figure 1. Epidemic Keratoconjunctivitis Treatment Picture
Figure 2. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Type in 2022
Figure 4. Topical Examples
Figure 5. Oral Examples
Figure 6. Global Epidemic Keratoconjunctivitis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Application in 2022
Figure 8. Hospital Pharmacy Examples
Figure 9. Retail Pharmacy Examples
Figure 10. Online Pharmacy Examples
Figure 11. Global Epidemic Keratoconjunctivitis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Epidemic Keratoconjunctivitis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Epidemic Keratoconjunctivitis Treatment Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Epidemic Keratoconjunctivitis Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Epidemic Keratoconjunctivitis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Epidemic Keratoconjunctivitis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Epidemic Keratoconjunctivitis Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Epidemic Keratoconjunctivitis Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 53. China Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Epidemic Keratoconjunctivitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Epidemic Keratoconjunctivitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Epidemic Keratoconjunctivitis Treatment Market Drivers
Figure 74. Epidemic Keratoconjunctivitis Treatment Market Restraints
Figure 75. Epidemic Keratoconjunctivitis Treatment Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Epidemic Keratoconjunctivitis Treatment in 2022
Figure 78. Manufacturing Process Analysis of Epidemic Keratoconjunctivitis Treatment
Figure 79. Epidemic Keratoconjunctivitis Treatment Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source

※参考情報

流行性角結膜炎（Epidemic Keratoconjunctivitis、EKC）は、主にアデノウイルスによって引き起こされる感染症で、眼の表面である角膜と結膜に炎症を引き起こします。この病気は非常に感染力が強く、集団感染が発生しやすいため、「流行性」と呼ばれています。特に学校や職場などの人が集まる場所での接触によって広がることが多いとされています。

EKCの特徴として、初期症状は結膜の充血や眼の異物感、涙が多く出ることなどがあります。通常、片目から始まり、数日内にもう一方の目に感染が広がることがあります。感染症の進行に伴い、目の腫れやかゆみが悪化し、場合によっては視力にも影響を及ぼすことがあります。また、EKCに伴う眼の痛みや眩しさも一般的で、日常生活に支障をきたすことがあります。

EKCの治療は主に対症療法が中心です。ウイルス性の感染症であるため、抗生物質は効かないため、目の炎症を和らげるためにステロイド点眼薬が用いられることがあります。しかし、ステロイド治療は慎重に行う必要があります。重篤なタバコや風邪のウイルスに対する抵抗力が低下する可能性があるため、長期的な使用は避けるべきです。また、冷湿布や人工涙液なども症状の緩和に役立ちます。

流行性角結膜炎には、アデノウイルスのいくつかの型が関与しており、特に型8、型11、型19が一般的な原因とされています。これらの型は、主に接触や飛沫感染を通じて広がります。例えば、感染した人が使用したタオルや手で目を触れることで、ウイルスが伝播します。したがって、EKCの予防には手指の衛生や、感染の疑いがある場合の眼への触れ合いを避けることが非常に重要です。

感染が広がる時期には、特に学生や職場環境での集団発生が見られるため、企業や学校などでの啓蒙活動が重要です。手洗いやタオルの共有を避けること、さらには症状が出た際にはすぐに眼科医に相談することが推奨されます。また、症状が改善されるまでの間は、必要に応じて社会生活を制限することも考慮すべきです。

関連技術としては、ケアの一環として使用される高度な診断技術があります。例えば、眼科診療には、顕微鏡検査や蛍光染色検査が用いられます。これにより、結膜の状態や角膜の損傷具合を評価し、感染の程度を判断します。また、最近ではPCR法と呼ばれる遺伝子検査が導入され、特定のウイルス株を早期に同定することが可能になりました。

流行性角結膜炎が発症した場合の注意点として、感染の広がりを防ぐために、感染が確認された場合は他の人との接触を最小限に抑え、自宅で休養することが重要です。また、公共の場での行動には注意が必要で、特に眼を擦らないよう心がけることが大切です。

流行性角結膜炎は、通常は軽度の症状で自己限定性の病気ですが、感染が重症化することもあります。特に高齢者や免疫力の低下した人々は注意が必要で、長期的な眼の異常や後遺症を引き起こすこともあります。しかし多くの場合、適切な治療と予防策により、健康な状態に戻ることができます。

EKCの研究も進展しており、新しいワクチンや治療法の開発が期待されています。特に、ウイルスに対する免疫反応を強化する研究は注目されています。将来的にはこれらの新技術が流行性角結膜炎の治療に変革をもたらすかもしれません。

このように流行性角結膜炎は、感染症としての側面と、眼科的な健康リスクを考慮した多面的な理解が必要な疾患です。感染を予防し、感染が広がった際には適切な対処が求められます。研究や治療法の進展により、今後はより効果的な対策が期待される分野でもあります。また、一般市民の意識向上も重要で、症状が出た際には早期に受診することが、流行を防ぐために非常に効果的です。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 流行性角結膜炎治療の世界市場2023-2029：局所、経口
  • 豚流行性脳炎不活化ワクチンのグローバル市場2023：マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組換え弱毒化生ワクチン
  • 世界の手湿疹（HE）治療市場2023年：企業・地域・タイプ・用途別分析
  • シュニッツラー症候群治療のグローバル市場2023：アナキンラ、リロシップ、カナキヌマブ、その他
  • カテーテル関連血流感染症治療のグローバル市場2023：抗菌剤、抗生物質
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23AG11425 )"流行性角結膜炎用治療のグローバル市場2023：局所式、経口式" (英文：Global Epidemic Keratoconjunctivitis Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。